Alnylam Assist™: Patient Support Program

Hi, I'm Kevin:
Your patient's local Case Manager

I'm here to support patients throughout their Alnylam treatment experience. I am specifically assigned to work with certain patients on questions they may have about Alnylam Assist™ and OXLUMO® (lumasiran).

1-833-256-2748

Monday - Friday, 8am - 6pm

Options for Getting Started

In order to make the process convenient for your patients, Alnylam Assist™ provides 3 separate options for initiating and completing the Start Form.

Together with your patient
(in office)

Alnylam Assist® electronic Start Form icon

Complete and submit the electronic Start
Form with your patient

Get Started

Alnylam assist® Start Form - To Print and Fax

Print, complete with your patient, and fax
the Start Form to 1-833-256-2747

Download

Initiate then send to patient
(via email)

Alnylam Assist® Start Form - To Email To Patient

Fill out your sections of the Start Form
and email to patient to complete
via DocuSign

Begin Start Form

DocuSign Instructions ›

What Services Does Alnylam Assist™ Offer to Patients?

Alnylam Assist™ offers support services to help your patients access Alnylam products.

Alnylam Assist® - Questions Icon

Find answers to other

Frequently Asked Questions ›

IMPORTANT SAFETY INFORMATION

Adverse Reactions
The most common (≥20%) adverse reaction reported in patients treated with OXLUMO was injection site reaction. Injection site reactions included erythema, swelling, pain, hematoma, pruritus, and discoloration.

Pregnancy and Lactation
No data are available on the use of OXLUMO in pregnant women. No data are available on the presence of OXLUMO in human milk or its effects on breastfed infants or milk production. Consider the developmental and health benefits of breastfeeding along with the mother’s clinical need for OXLUMO and any potential adverse effects on the breastfed child from OXLUMO or the underlying maternal condition.

INDICATION

OXLUMO® (lumasiran) is indicated for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary and plasma oxalate levels in children and adults.

For additional information about OXLUMO, please see the full Prescribing Information.